Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL8450325 | 1.00 | SLC34A1 (0.42) | SLC34A1LMNAMAPT | |
| Phosphoric Acid SCHEMBL28975729 | 1.00 | SLC34A1 (0.42) | SLC34A1LMNAMAPT | |
| Phosphoric Acid SCHEMBL104833 | 1.00 | SLC34A1 (0.42) | SLC34A1LMNAMAPT | |
| Phosphoric Acid SCHEMBL29189684 | 1.00 | SLC34A1 (0.42) | SLC34A1LMNAMAPT | |
| Phosphoric Acid SCHEMBL28408970 | 1.00 | SLC34A1 (0.42) | SLC34A1LMNAMAPT | |
| Phosphoric Acid SCHEMBL11883861 | 1.00 | SLC34A1 (0.42) | SLC34A1LMNAMAPT | |
| Phosphoric Acid SCHEMBL23581849 | 1.00 | SLC34A1 (0.42) | SLC34A1LMNAMAPT | |
| Phosphoric Acid SCHEMBL467211 | 1.00 | SLC34A1 (0.42) | SLC34A1LMNAMAPT | |
| Phosphoric Acid SCHEMBL11565845 | 1.00 | SLC34A1 (0.42) | SLC34A1LMNAMAPT | |
| Phosphoric Acid SCHEMBL210785 | 1.00 | SLC34A1 (0.42) | SLC34A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 282 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4051246-B1 | BILAYER TABLET FORMULATIONS COMPRISING DAPAGLIFLOZIN AND METFORMIN | SANOVEL ILAC SANAYI VE TICARET AS (TR) | 2026-03-18 | — | — | EP | claimed |
| EP-4563143-A1 | A BILAYER TABLET FORMULATION OF METFORMIN AND SITAGLIPTIN COMPRISING ANTIOXIDANT | Sanovel Ilac Sanayi ve Ticaret A.S. (TR) | 2025-06-04 | — | — | EP | claimed |
| WO-2025106043-A1 | A BILAYER TABLET COMPOSITION COMPRISING DAPAGLIFLOZIN AND METFORMIN | SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2025-05-22 | — | — | WO | claimed |
| EP-4556001-A1 | A BILAYER TABLET COMPOSITION COMPRISING DAPAGLIFLOZIN AND METFORMIN | Sanovel Ilac Sanayi ve Ticaret A.S. (TR) | 2025-05-21 | — | — | EP | claimed |
| EP-4531829-A1 | A TABLET COMPRISING EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi (TR) | 2025-04-09 | — | — | EP | claimed |
| EP-4531828-A1 | A BILAYER TABLET FORMULATION COMPRISING EMPAGLIFLOZIN AND METFORMIN | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi (TR) | 2025-04-09 | — | — | EP | claimed |
| EP-4531830-A1 | A FORMULATION COMPRISING EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi (TR) | 2025-04-09 | — | — | EP | claimed |
| EP-4497434-A1 | A FILM COATED TABLET FORMULATION COMPRISING EMPAGLIFLOZIN | Sanovel Ilac Sanayi ve Ticaret A.S. (TR) | 2025-01-29 | — | — | EP | claimed |
| WO-2024162930-A1 | FILM COATING TABLETS OF EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2024-08-08 | — | — | WO | claimed |
| EP-4410280-A1 | FILM COATING TABLETS OF EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | SANOVEL ILAC SANAYI VE TICARET A.S. (TR) | 2024-08-07 | — | — | EP | claimed |
| US-20110223245-A1 | CONTROLLED-RELEASE FORMULATIONS OF PRAMIPEXOLE | Sanovel IIac Sanayi Ve Ticaret Anonim Sirketi (TR) | 2011-09-15 | — | — | US | claimed |
| EP-2364694-A1 | Controlled-release formulations of pramipexole | Sanovel Ilac Sanayi ve Ticaret A.S. (TR) | 2011-09-14 | — | — | EP | claimed |
| EP-2363120-A1 | Combinations of dimebolin and memantine | Sanovel Ilac Sanayi ve Ticaret A.S. (TR) | 2011-09-07 | — | — | EP | claimed |
| EP-2359816-A1 | Aripiprazole formulations | Sanovel Ilac Sanayi ve Ticaret A.S. (TR) | 2011-08-24 | — | — | EP | claimed |
| US-20100331996-A1 | METHOD OF INSTALLING A TRANSCUTANEOUS PROSTHESIS | UNIVERSITY COLLEGE LONDON (GB) | 2010-12-30 | — | — | US | claimed |
| US-20090149966-A1 | TRANSCUTANEOUS PROSTHESIS | UNIVERSITY COLLEGE LONDON (GB) | 2009-06-11 | — | — | US | claimed |
| US-20070073412-A1 | Transcutaneous Prosthesis | UNIVERSITY COLLEGE LONDON (GB) | 2007-03-29 | — | — | US | claimed |
| EP-1519998-A1 | SYSTEM AND METHOD FOR REMOVING PARTICLES FROM A WELL BORE | Halliburton Energy Services, Inc. (US) | 2005-04-06 | — | — | EP | claimed |
| WO-2004003101-A1 | SYSTEM AND METHOD FOR REMOVING PARTICLES FROM A WELL BORE | HALLIBURTON ENERGY SERVICES, INC. (US) | 2004-01-08 | — | — | WO | claimed |
| US-20040000434-A1 | System and method for removing particles from a well bore penetrating a possible producing formation | HALLIBURTON ENERGY SERVICES, INC. | 2004-01-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110223245-A1 | CONTROLLED-RELEASE FORMULATIONS OF PRAMIPEXOLE | LPXN, CENPE, SMAD3 | SLC34A1 1095/4885LMNA 2549/4885MAPT 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.